This document discusses the management of infertility and provides guidelines on evaluating and treating different causes of infertility. It covers investigations and treatments for male factor infertility, endometriosis-associated infertility, and ovarian factor infertility. Key points include recommendations on when to refer couples for infertility testing based on age, tests to classify infertility factors by association with pregnancy rates, and laparoscopy and ultrasound as primary investigations for diagnosing endometriosis. The document provides an overview of evaluating and treating different infertility etiologies.
Ovarian Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda JainLifecare Centre
The Best Gametes
Give The Best Result
OVARIAN RESERVE
Plan fertility preservation
Fertility outcome
Response to ovarian stimulation
Predict pregnancy rate
Monitor fertility decline
Fertility after chemotherapy and cancer treatment
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
Significant increase in live birth rate is found when IUI is done with stimulation compared with IUI in natural cycle in women with Unexplained Infertility .
Ovarian Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda JainLifecare Centre
The Best Gametes
Give The Best Result
OVARIAN RESERVE
Plan fertility preservation
Fertility outcome
Response to ovarian stimulation
Predict pregnancy rate
Monitor fertility decline
Fertility after chemotherapy and cancer treatment
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
Significant increase in live birth rate is found when IUI is done with stimulation compared with IUI in natural cycle in women with Unexplained Infertility .
Normal fertile couples of reproductive age have a conception rate of 20% to 25% per month, with more than 90% conceiving within 1 year.
Male factor infertility is involved in approximately 50% of infertile couples.
In 30% of the cases, an abnormality is discovered solely in the man.
As many as 2% of all men will exhibit suboptimal sperm parameters.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
3. INTRODUCTION
When to refer a couple for investigations?
After 40 y
Immediate evaluation in women.
35-40 Y
After 6 months of unprotected intercourse without
conception
<35 y
After one year
ABOUBAKR ELNASHAR
4. European Society of Human Reproduction &
Embryology (ESHRE) (2000)
Infertility testing should be classified into 3 groups
depending on correlation with pregnancy rates
I. Tests that have an established association with
pregnancy:
1. Conventional semen analysis
2. Tubal patency tests,
3. Tests of ovulation
ABOUBAKR ELNASHAR
5. II. Tests that are not consistently associated with
pregnancy:
Post-coital test,
Antisperm antibody tests
Zona-free hamster egg penetration test
III. Tests that have no association with pregnancy:
Endometrial biopsy
Premenstrual endometrial biopsy
Varicocele assessment
Chlamydia testing
ABOUBAKR ELNASHAR
6. 1. MALE INFERTILITY
Prof. Aboubakr Elnashar
Benha University, Egypt
elnashar53@hotmail.com
ABOUBAKR ELNASHAR
7. I. STANDARD SEMEN
ANALYSIS
IV. GENETIC TESTS
1. Karyotyping
2. Y chromosome microdeletions
3. Cystic fibrosis conductance
regulator (CFTR) gene
mutation
II. SPECIALIZED
SEMEN ANALYSIS
1. Sperm
autoantibodies
2. Semen Fructose
3. Semen culture
4. Sperm function
tests
CASA
S DF
S ROS
III. ENDOCRINE TESTS
1. T
2. LH and FSH
3. Prolactin
INVESTIGATIONS
ABOUBAKR ELNASHAR
8. I. STANDARD SEMEN ANALYSIS
A. Macroscopic
1. Delayed liquefaction
2. Increased viscosity
3. Semen volume
4. pH
B. Microscopy
1. Agglutination
2. Concentration
3. Motility
4. Morphology
5. Round cells
6. Leukocytes
ABOUBAKR ELNASHAR
9. Semen analysis: WHO, 2010
:
:
Lower reference limitParameter
1.5 mlVolume
7.2pH
15 million/mlConcentration
39 million/ejaculateTotal sperm number
40% or
PR: 32%
Total motility: (PR+NP)
58% live spermatozoaVitality
4% (strict criteria).Normal forms
Motility: progressive: rapid (a)+ slow (b)
A and b Not used in WHO 2010
Non progressive (c) ABOUBAKR ELNASHAR
10. Prediction of fertility
The likelihood of infertility
increased with decreases in any of the 3
parameters:
M
NM
C
Normal morphology
had the greatest discriminatory power.
ABOUBAKR ELNASHAR
11. II. SPECIALIZED SEMEN ANALYSIS
Not routinely performed
used to determine the cause of male infertility
1. Sperm autoantibodies
2. Semen biochemistry (semen fructose)
3. Semen culture
4. Sperm cervical mucus interaction tests
5. Sperm function tests
Computer aided sperm analysis (CASA)
Sperm chromatin/DNA assays
Sperm reactive oxygen species generation
ABOUBAKR ELNASHAR
12. 1. Sperm autoantibodies
4 to 8%of subfertile men.
Agglutination:
Stick of motile spermatozoa to each other.
≥10%:
suggestive but not conclusive of immunological
infertility.
should be confirmed by
Mixed antiglobulin reaction (MAR)
Immunobead test
both of which detect sperm surface antibodies.
ABOUBAKR ELNASHAR
13. 2. Semen biochemistry
Rarely useful in clinical practice.
Fructose
marker of seminal vesicle function.
Low or non-detectable:
congenital absence of the vas deferens and
seminal vesicles or
ejaculatory duct obstruction
ABOUBAKR ELNASHAR
14. 3. Semen culture
Indicated:
semen samples contain inflammatory cells
Precautions
during sample collection to prevent skin
contamination.
Results:
usually not diagnostic.
The yield of semen culture
may be improved by performing a prostatic massage
before sample collection.
ABOUBAKR ELNASHAR
15. 5. Sperm function tests
Routine:
Impractical and costly
Selective
when the standard semen analysis is normal or
near normal
ABOUBAKR ELNASHAR
16. Computer-aided sperm analysis: CASA
Assess:
1. Concentration
2. Morphology.
3. Motility:
Quantitative measurement
(curvilinear, straight line, average path)
Amplitude of lateral displacement
other derived functions.
ABOUBAKR ELNASHAR
17. Useful in:
Male unexplained infertility
predicting in vivo and in vitro fertilizing capacity,
toxicology studies.
Accuracy depend upon:
technology
analytic conditions
technical training of the operators.
ABOUBAKR ELNASHAR
19. Normal= 10
Fragmented= 4
DFI= 4X100/10+4
=28.5%
normal
normal
normal
normal
normal
normal
normal
normal
normal
fragmented
fragmented
fragmented
fragmented
normal
≥30: male infertility
15-30: RM.
≤15: Excellent to Good fertility potential
ABOUBAKR ELNASHAR
20. There is insufficient evidence to recommend the routine
use of SDF testing in evaluation and treatment of
infertile couple {level C}
?????????
For diagnostic test
1. Results must be reproducible
2. Applicable to a given patient
3. Change management of patient
ABOUBAKR ELNASHAR
21. III. ENDOCRINE TESTS
1. Serum testosterone (T)
2. Serum LH and FSH
3. Prolactin
ABOUBAKR ELNASHAR
22. 1. Serum testosterone (T)
Morning T
In men with borderline values:
Repeat
FT
ABOUBAKR ELNASHAR
23. 2. Serum LH and FSH
Indication:
T is low
Interpretation:
high FSH and LH:
primary hypogonadism
low or normal:
secondary hypogonadism.
low LH + low sperm counts +well-androgenized:
exogenous anabolic or
androgenic steroid abuse.
ABOUBAKR ELNASHAR
24. 3. Prolactin
Indication:
low T
normal to low LH
4. Inhibin
low serum inhibin concentrations may be an even
more sensitive test of primary testicular dysfunction
than high serum FSH concentrations, provided the
assay is specific for inhibin B
ABOUBAKR ELNASHAR
25. IV. GENETIC TESTS
1. Karyotyping
2. Y chromosome microdeletions
3. Cystic fibrosis conductance regulator (CFTR)
gene mutation
ABOUBAKR ELNASHAR
27. Abnormal semen
ICSI
TT of varicocele if palpable
Hormonal tt if low FSH &Testost.
Treatment of infection ?
Mild:≥2 NM, ≥5M, ≥10%TM
Severe or
Azoospermia
3 trial IUI
ABOUBAKR ELNASHAR
TREATMENT
28. Varicocele:
(AUA&ASRM, 2004 & AFU, 2006)
Imaging examinations:
not indicated to characterize the varicocele.
TT when all of the following conditions are
present:
1. Varicocele: Palpable
2. Semen: Abnormal (at least one abnormality)
3. Couple's infertility: Documented
4. Female infertility problem: Curable
ABOUBAKR ELNASHAR
30. INVESTIGATIONS
1. Laparoscopy
with biopsy and histology:
gold standard for diagnosis
Negative diagnostic laparoscopy:
highly accurate for excluding endometriosis
Positive laparoscopy without taking biopsies
less informative
of limited value
(Wykes et al., 2004).
To obtain tissue for histology in women undergoing
surgery for
endometrioma and/or
deep infiltrating disease
{exclude rare instances of malignancy}
{GPP}
ABOUBAKR ELNASHAR
34. Endometrioma. Sagittal TVS
an ovarian mass with multiple fine internal echoes (arrows) and
several hyperechoic mural foci (arrowheads).
ABOUBAKR ELNASHAR
35. Ovarian endometrioma (A, B).
The structure is hypoechoic and exhibits low amplitude
uniformly distributed echotexture in the cavities of the
cysts.ABOUBAKR ELNASHAR
36. 3D ultrasound
To diagnose rectovaginal endometriosis is not
well established
(Pascual et al., 2010).{D}
MRI
To diagnose peritoneal endometriosis is not well
established
(Stratton et al., 2003) {D}
ABOUBAKR ELNASHAR
39. INVESTIGATIONS
Routine
1. Ultrasound folliculometry
Costly
Time consuming
To be reserved for induction ovulation or COS
(NICE, 2013; Practice Committee of the ASRM, 2015;
UpToDat,2016)
ABOUBAKR ELNASHAR
40. Diagnosis of Spontaneous Ovulation
1. Mature F. (contain mature oocyte) = 17 – 25 mm (Inner
dimensions)
2. Reduction in mature follicle size (40%) Or
Disappearance (60%)
3. Intra peritoneal fluid
-Normal: 1-3 ml
-With ovulation: 4- 5 ml
4. CL: 4-8 days after ovulation
Irregular thick wall .
Hypoechoic
May contain internal echos (hge.)
15 mm
ABOUBAKR ELNASHAR
41. 2. Mid luteal serum progesterone
in regular and irregular cycles
Mid-luteal
7 days before the next expected period
day 21 and day 28 in 28-day and 35-day cycles,
respectively.
In irregular prolonged cycles
depending upon the timing of menstrual periods,
conducted later in the cycle (for example day 28 of a
35-day cycle) and repeated weekly thereafter until the
next menstrual cycle starts
Advantages:
Reliable
Safe
Inexpensive
ABOUBAKR ELNASHAR
42. 3. LH surge in urine
Commercially available urinary LH detection kits can
detect the LH surge and can be used to time
intercourse with ovulation induction
Inexpensive,
Pinpoint the day of ovulation
Reduced the uncertainty in interpretation of
progesterone levels by better-identifying the time of
peak progestrone secretion at which to obtain serum
ABOUBAKR ELNASHAR
43. May be done
1. Basal FSH and LH
Only in
irregular prolonged cycles
2. Prolactin
Only in
ovulatory disorder
galactorrhoea or
pituitary tumour
3. TSH:
only if
symptoms of thyroid disease
ABOUBAKR ELNASHAR
44. 4. Ovarian reserve testing
Woman’s age:
An initial predictor of overall chance of success
through natural conception or with IVF
Predictors of ovarian response to Gnt stimulation
High responseLow response
16 or more4 or lessTotal AFC
3.5 or more
25
0.8 or less
5.5
AMH
ng/ml
pmol/l
Conversion ratio:7
4 or less8.9 or moreFSH IU/L
ABOUBAKR ELNASHAR
45. Do not use
ovarian volume
ovarian blood flow
inhibin B
E2
ABOUBAKR ELNASHAR
46. Not recommended
Historically, the effects of progesterone on basal body
temperature, endometrial histology or cervical mucus
were commonly used.
1. PMEB:
histologic dating is not a valid diagnostic method
lacks both accuracy and precision
To evaluate the luteal phase: No
{no evidence that medical tt of luteal phase defect
improves pregnancy rates]
ABOUBAKR ELNASHAR
47. 2. BBT
Stressful
Predicted the day of ovulation in10% of cycles
Less accurate for confirming ovulation
(Guermandi et al, 2001)
ABOUBAKR ELNASHAR
49. Types of ovarian stimulation
Controlled ovarian
stimulation
Super
ovulation
Induction of
ovulation
Anovulatory or ovulatoryAnovulatoryPatient
Multiple> oneOne mature
follicle
Objective
IVFIUI
Unexp infert
AnovulatoryExample
Down regulation
Stimulation
Prevent premature
LH surge
StimulationStimulationMethod
ABOUBAKR ELNASHAR
50. Amenorrhea or severe oligomenorrhea
FSH & LH: low
Prolactin: normal
I. Hypogonadotrophic hypoestrogenic
Type I
ABOUBAKR ELNASHAR
51. 1. Reverse the life style factors:
Increase wt if BMI <19
When the metabolic state is normalized reflected
by a normal BMI (>20 kg/m2), a regular menstrual
cycle will be restored in the majority of patients.
(Stafford, 2005)
Moderating exercise if high levels of exercise.
Treat stress
CC:
not effective
ABOUBAKR ELNASHAR
52. 2. Gonadotrphins with LH activity or
Pulsatile GnRH (pump)
3. luteal support
hCG or progesterone from time of ovulation induction
until sufficient hCG production by trophoblast
cells is necessary.
(Beckers et al., 2006)
ABOUBAKR ELNASHAR
53. II. Normogonadotrophic Normoestrogenic
Type II
PCOS
2 of 3 (Roterdam definition,2003):
•U/S PCO
•Hyperandrogenism (Clinical or Laboratory)
•Irregular or absent ovulation
ABOUBAKR ELNASHAR
54. Weight reduction
letrozole or CC
Obese &overweight
Normal weight &No weight loss & No ovulation
LODGnT
No ovulation after 3 cycles.
No pregnancy after 6 cycles.
No pregnancy
after 6 cycles.
No pregnancy after spontaneous,
CC, FSH ovulation
IVF
Other surgical indication
Difficult follow up
Less aggressive
No desire for
surgery
Add metformin
IGT &IR
ABOUBAKR ELNASHAR
56. 1. Oral contraceptive suppression of gonadotrpins
followed by discontinuation
to allow a rebound in gonadotropins & ovarian
function.
2. GnRHa suppression of gonadotropins secretion
followed by high dose gonadotropin injection
3. Glucocorticoids suppression of immune system.
Non of these tts has demonstrated efficacy in RCT
ABOUBAKR ELNASHAR
57. IV. Hyperprolactinaemia
I. Idiopathic
Dopamine agonist (anxiety, pregnancy).
Stop during pregnancy
II. Microadenoma
Dopamine agonist (anxiety, pregnancy).
Stop after 2-3 yr.
Surgery (rapid growth).
III. Macroadenoma
Dopamine agonist: long term
Surgery
(No response, suprasellar extension, pregnancy).
ABOUBAKR ELNASHAR
59. INVESTIGATIONS
1. Hysterosalpingography
The most commonly performed screening test for tubal
patency.
Advantages:
1.Position of tubal occlusion
2. Unilateral patency can be dd from bilateral patency.
3. Degree of damage to tubal endothelium
4. Peritubal adhesion.
5. Uterine cavity
ABOUBAKR ELNASHAR
60. 6. Relatively cheap & simple.
7. HSG is in agreement with the laparoscopic
findings approximately two thirds of the time.
Sensitivity: 73
Specificity: 83%
High specificity makes it useful in ruling in tubal
obstruction
ABOUBAKR ELNASHAR
61. Disadvantages
1. The pelvis including the ovaries is exposed to
radiation:
significant problem if the patient had an early
pregnancy.
2. Abdominal pain
which peaks 5 min after starting
usually settles within 30 min.
ABOUBAKR ELNASHAR
62. 3. Intravasation
Network of streaklike opacities adjacent to the
uterine cavity
extend toward the pelvic side walls and
subsequently migrate in a cephalad direction.
Early detection:
minimizes complications
injection should be discontinued
immediately, regardless of the contrast
medium used.
ABOUBAKR ELNASHAR
63. 2. Sono hystero salpingography
An US contrast dye or saline (10-40 ml) is injected into
the uterus through the cervix by a Foley catheter
the passage of the dye is followed by TVS.
76% concordance rate with laparoscopy dye
The addition of pulsed wave or color Doppler imaging
may improve the predictive value of TV
sonosalpingography
Experience
effective alternative to HSG
(NICE, 2013)
The ideal test is HyCoSy which combines cavity check
with tubal assessment.
ABOUBAKR ELNASHAR
64. 3. Laparoscopy
Indication
1. Abnormal HSG or US
2.History or symptoms suggestive of pelvic disease.
Normal HSG or no history suggestive of tubal disease:
probability of clinically relevant tubal disease or
endometriosis is very low:
laparoscopy is not justified or cost effective
(Fatum et al, 2002).
ABOUBAKR ELNASHAR
65. Hysteroscopy
Not an initial investigation unless clinically
indicated
{effectiveness of surgical treatment of uterine
abnormalities on improving pregnancy rates has not
been established}.
(NICE, 2013)
ABOUBAKR ELNASHAR
66. 4. Transvaginal hydrolaparoscopy (THL)
±Method of choice for the clarification of mechanical
infertility factors in symptom free patients with no
suspicion of pelvic pathologies
(Nawroth et al,2001).
THL in association with minihysteroscopy:
more information
better tolerated than HSG in outpatient infertility
investigation
ABOUBAKR ELNASHAR
67. 5. Chlamydia antibody testing (CAT)
HSG is more accurate than CAT in predicting tubal
disease
(Elnashar et al,2000).
If both tests were negative
the tubal disease was identified on laparoscopy in
only 4 % of case.
ABOUBAKR ELNASHAR
68. TREATMENT
IVF
Main player for tt of tubal factor.
Indication
1. Moderate to severe tubal disease
A. Distal tubal occlusion with hydrosalpiges >1.5 cm in
diameter.
B. Distortion of the intraluminal architecture or
endotubal adhesions detected by HSG, salpingoscopy or falloscopy
2. Other factors
A. Sperm dysfunction
B. Age >36 yr
ABOUBAKR ELNASHAR
69. 1. Laparoscopic Surgery:
Fimbrioplasty
Lysis of fimbrial adhesions or the dilation of
fimbrial strictures.
Neosalpingostomy
Creation of a new opening in a fallopian tube with
a distal occlusion.
Adhesiolysis
more likely to work in the presence of patent tubes
& filmy adhesions
ABOUBAKR ELNASHAR
70. 2. Transcervical cannulation of the proximal fallopian
tube
Methods
hysteroscopy
fluoroscopy, or
sonography
Results
successful catheterization
80% to 90%
cumulative pregnancy
23% and 39% within the first 6 to 12 months.
Ectopic pregnancy
5% to 13%
ABOUBAKR ELNASHAR
71. Selective salpingography plus tubal catheterisation,
or hysteroscopic tubal cannulation
Proximal tubal disease
If pregnancy has not occurred within 12 mo of
surgery: IVF
ABOUBAKR ELNASHAR
72. 3. Microsurgical reanastomosis of the fallopian
tubes:
for tubal ligation reversal.
performed by
Laparotomy
Laparoscopy
comparable rates of success
ABOUBAKR ELNASHAR
73. IVF or ICSI:
IVF should be the initial treatment of choice
(Aboulghar et al,1996; Bukulmez et al,2000).
{No significant difference in PR. or take-home baby}.
ABOUBAKR ELNASHAR
74. Hydrosalpinges
salpingectomy, or tubal disconnection
preferably by laparoscopy, before IVF treatment
{improves the chance of a live birth}.
ABOUBAKR ELNASHAR
78. 1. HSG
Assess
patency of the fallopian tubes
contour of the endometrial cavity
presence of any complex communications in the
setting of a müllerian anomaly.
Disadvantages:
1. Sensitivity to detect intrauterine abnormalities
can be as low as 50%
2. lack of information about the external uterine
contour: limits its utility for evaluating a uterine
anomaly.
use of TVS or HSG to evaluate the uterine cavity
in women with suspected abnormalities may lead to
suboptimal assessment of the uterus.
ABOUBAKR ELNASHAR
79. 2. TVS
Routine diagnostic tool for assessment of the pelvis,
including the uterus and adnexa.
Timing:
Secretory phase of the menstrual cycle:
better visualization of the endometrium, and
contour of the uterine cavity.
Advantages:
Specificity and sensitivity for detecting uterine
abnormalities: high
Accuracy:
excluding endometrial hyperplasia: high
Disadvantages:
dd SM fibroids & polyps: low (A).
ABOUBAKR ELNASHAR
80. Information
Uterus Assessment: Dimension, Endometrial: thickness, appearance
Abnormalities: Anomalies, Tumors
Ovaries Assessment: Position, Mobility, Volume, AFC
Abnormalities: PCOS, Cysts, Tumors
Tube Hydrosalpinx, Patency
Pelvis Free fluid, Mass
Basal Vaginal U/S
The Pivotal US (performed D8-12)
± Saline infusion sonography (SIS)
ABOUBAKR ELNASHAR
81. 3. SIS:
experience
effective alternative to HSG
(NICE, 2013)
Effectively delineate
intracavitary space
internal and external uterine contours.
Most accurate for evaluating the size, location,
and intracavitary component of the myoma.
SIS Vs office hysteroscopy:
•Comparable
•easier
•less uncomfortable
•less expensive
ABOUBAKR ELNASHAR
82. 4. 3 DUS
highly accurate imaging of pelvic anatomy
including detailed assessment of the uterus.
ABOUBAKR ELNASHAR
83. 5. MRI
Excellent delineation of internal and external
uterine contours
gold standard ” for the diagnosis of
müllerian anomalies
can identify rudimentary uterine structures and
the presence of unctional endometrium.
can differentiate
leiomyomas, adenomyosis and adenomyomas.
ABOUBAKR ELNASHAR
84. Hysteroscopy
As a routine procedure in the infertility work-up:
still under debate
no consensus on its efficacy and effectiveness in improving the
prognosis of infertile couples
(Sardo et al., 2016).
Not an initial investigation unless clinically
indicated
(NICE, 2013)
{its effectiveness on improving reproductive
outcome has not been established }
ABOUBAKR ELNASHAR
86. TREATMENT
1. CONGENITAL (MULLERIAN) ANOMALIES
Prevalence
Fertile and infertile women
3 – 4%
Normal reproductive outcomes
3.2%
1st T RM:
5%-10%
2nd T RM:
25%
(Khati, et al., 2012; Grimbizis et al., 2016).
ABOUBAKR ELNASHAR
87. I- Uterine septum for primary infertility: (NICE 2015)
Current evidence on efficacy is inadequate:
should only be done:
Multidisciplinary team
specialists in reproductive medicine
uterine imaging
hysteroscopic surgery.
Clear written consent:
uncertain efficacy
risks
audit or research
special arrangements for clinical governance
ABOUBAKR ELNASHAR
88. II. Unicornuate uterus
(with obstructed uterine horn)
{at higher risk for infertility, endometriosis, premature
labor, and breech presentations}.
Excision of the obstructed rudimentary blind horn
prevent
endometriosis by eliminating reflux
development of a pregnancy (and pregnancy
complications) in the obstructed uterine horn
(Khati, et al., 2012) .
ABOUBAKR ELNASHAR
89. III. The Mayer-Rokitansky-Küster-Hauser syndrome
=congenital absence of the vagina with variable
uterine development
{müllerian agenesis}.
(Iverson et al ., 2016)
2014:
First live birth following uterus transplantation
uterine factor infertility, even when considered
absolute, is now treatable
(Brannstrom et al. 2015).
3 more births proving the outcome of uterus
transplantation in this early stage of clinical
implementation to be astonishing
(Brannstrom 2015)
ABOUBAKR ELNASHAR
90. 2. FIBROID
Prevalence
Women of reproductive age
20- 40%
Associated with infertility:
5- 10%.
Only cause of infertility:
2- 3%
ABOUBAKR ELNASHAR
91.
92. Indications of Myomectomy:
1. Distorting the cavity
Submucous:
(Gambadauro,2012).
Intramural:
2. Not distorting
1. >5 cm
2. Multiple >3 (3 cm)
(Bajekal & Li, 2000)
3. only cause of infertility
Myomectomy of IM fibroid not distorting cavity:
no study has yet confirmed improvement of
outcome
(Paulson, 2016; Khalaf ,2016)
ABOUBAKR ELNASHAR
93. 3. ADENOMYOSIS
Diagnosis:
1. TVS: 3 or more of the followings:
1. Globular uterus: 95% of cases.
2. Asymmetrical thickening: Anterior or posterior myometrial
wall appearing thicker than its counterpart
3. Mottled heterogeneous myometrial texture: All cases.
4. Small myometrial hypoechoic cysts, which are cystic
glands within ectopic endometrial foci: 82%.
5. “Shaggy” indistinct endometrial strips: 82%.
6. Striated projections extending from the endometrium into
the myometrium
ABOUBAKR ELNASHAR
94. Adenomyosis. Sagittal TVS
Globular uterine enlargement
Asymmetric thickening
Heterogeneity of the myometrium (arrows)
Poor definition of the endomyometrial junction
(arrowheads). E = endometrium.
ABOUBAKR ELNASHAR
100. Treatment: (Tsui et al, 2015).
1. Routine infertility investigation plus ORT
Normal: long agonist protocol and natural
conception
Abnormal: IVF
2. Failed natural conception or IVF:
repeat IVF
3. Failed IVF:
conservative surgery
IVF after 3 m
(Tsui et al, 2015).
ABOUBAKR ELNASHAR
101. 4. ENDOMETRIAL POLYPS
Define:
hyperplastic overgrowths of endometrial glands
and stroma that forms a projection from the
surface of the endometrium
(Stewart 2016).
ABOUBAKR ELNASHAR
104. Treatment
Hysteroscopic adhesolysis.
The goal is to restore the size and shape of the uterine cavity,
as well as endometrial function and fertility
(Yu et al., 2008).
An experienced hysteroscopic surgeon.
Guidance with US:
help define the cervical canal and the junction between
the cervical internal os and the intrauterine cavity
guide dissection.
A small (5 mm) rigid hysteroscope can be used to pass
through the cervical canal and into the uterine cavity under
direct visualization to decrease the creation of a false passage
(Cedars and Yanett, 2016).
ABOUBAKR ELNASHAR
105. 6. REFRACTORY ENDOMETRIUM
Prevalence
Low: 2.4%
(Kasius et al., 2014),
Causes
I. Surgical:
dilation and curettage
partial ablation
aggressive myomectomy
II. Radiotherapy
III. Infections
IV. Congenital Müllerian anomalies
V. Idiopathic
ABOUBAKR ELNASHAR
106. According to the most recent evidence:
EnT≤7 mm would define a refractory
endometrium with compromised success rates
(Dix and Check, 2010; Kasius et al., 2014).
ABOUBAKR ELNASHAR
107. Treatment
I. Hysteroscopic adhesiolysis
II. Hormonal manipulation
Estrogen:High dose 6−8 mg from cycle day 1
High doses for long periods, up to 9 ws
vaginal
HCG injection in the proliferative phase:1500 iu SC, daily
starting from day 8 of the cycle For 7 days or until EnT 7mm
Midluteal GnRHa:
Single dose: Triptorelin: 0.1 SC 6 days after ICSI.
Multiple doses: Triptorelin: daily 0.1 mg SC until day of beta-HCG or
14 days after OR
ABOUBAKR ELNASHAR
108. III. Improving endometrial perfusion
LDA
Pentoxifylline and vitamin E. Pentoxifylline: 800 mg vit E:
1000 IU daily for 6-9 months
Sildenafil: 25 mg/6 h in vaginal supp in the proliferative phase,
stopped prior to HCG administration or ET.
L-arginin: 6 g/day
Nitroglycerin
IV. New modalities
Granulocyte colony-stimulating factor
Autologous platelet-rich plasma
Endometrial stem cells from bone marrow
ABOUBAKR ELNASHAR
110. DEFINITION
Inability to conceive (before 35 y)
after one year
with routine (standard, basic) investigations of
infertility showing no abnormality.
(RCOG guidelines,1998; Randolph,2000)
ABOUBAKR ELNASHAR
111. INVESTIGATIONS
Tests that have an established association with
pregnancy:
1. Conventional semen analysis
2. Tubal patency tests,
3. Tests of ovulation
35-40
After 6 months
After 40 y
Immediate evaluation in women.
ABOUBAKR ELNASHAR
112. Laparoscopy should be omitted in couples with
unexplained infertility
1.Laparoscopy may reveal
minimal or mild endometriosis or
peritubal adhesions:
Surgery or medical tt has not been proven to
improve fecundity.
2. In women with unexplained infertility
laparoscopy did not increase the PR
(Badawy et al, 2010)
ABOUBAKR ELNASHAR
113. Hysteroscopy
Not routine in investigation of infertility
except when an intrauterine lesion is suspected.
Not an initial investigation
unless clinically indicated
{effectiveness of surgical treatment of uterine
abnormalities on improving pregnancy rates has not
been established}.
(NICE, 2013)
ABOUBAKR ELNASHAR
114. TREATMENT
By definition: Empiric
{does not address a specific defect or functional impairment}
(Soules,2000 , Balen,2003; ASRM, 2006)
Dependent on:
Resources
Patients’ age
Duration of infertility.
The standard protocol is to:
Progress from simple to complex
Balance the effectiveness against the cost and
side effects.
(Ray et al,2012)
ABOUBAKR ELNASHAR
115. Lines of treatment
I. Expectant management (EM)
II. Ovulation-inducing agents
1. CC:
2. Aromatase inhibitors (AI)
3. Gonadotropins
III. IUI
IV. ICSI
Tubal flushing or perturbation
Fallopian tube sperm perfusion
ABOUBAKR ELNASHAR
116. Protocol for Management
(Ray et al, 2012)
6
4
2
ABOUBAKR ELNASHAR
117. ABOUBAKR ELNASHAR
You can get this lecture from:
1.My scientific page on Face book:
Aboubakr Elnashar Lectures.
https://www.facebook.com/groups/2277
44884091351/
2.Slide share web site
3.elnashar53@hotmail.com